Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy.

Autor: Wadsley J; Weston Park Hospital, Sheffield, United Kingdom., Ainsworth G; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom., Coulson AB; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom., Garcez K; Christie NHS Foundation Trust, Manchester, United Kingdom., Moss L; Velindre Cancer Centre, Cardiff, United Kingdom., Newbold K; The Royal Marsden NHS Foundation Trust, London, United Kingdom., Farnell K; Butterfly Thyroid Cancer Trust, NCCC Freeman Hospital, Newcastle, United Kingdom., Swain J; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom., Howard H; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom., Beasley M; Bristol Haematology and Oncology Centre, Bristol, United Kingdom., Weaver A; Oxford Churchill Hospital, Oxford, United Kingdom., Wood K; Royal Surrey County Hospital, Guildford, United Kingdom., Marshall J; University Hospital Southampton, Southampton, United Kingdom., Griffin M; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom., Pascoe A; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom., Du Y; The Royal Marsden NHS Foundation Trust, London, United Kingdom., Taprogge J; Joint Department of Physics, Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.; The Institute of Cancer Research, London, United Kingdom., Flux G; Joint Department of Physics, Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.; The Institute of Cancer Research, London, United Kingdom., Brown S; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.

Publikováno v: Thyroid : official journal of the American Thyroid Association [Thyroid] 2023 Sep; Vol. 33 (9), pp. 1119-1123. Date of Electronic Publication: 2023 Sep 01.

Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial.

Autor: Royle KL; Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK K.L.Royle@leeds.ac.uk., Coulson AB; Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK., Ramasamy K; Radcliffe Department of Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Cairns DA; Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK., Hockaday A; Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK., Quezada S; Department of Haematology, UCL Cancer Institute, London, UK., Drayson M; Clinical Immunology Service, Institute of Immunology and Immunotherapy, Medical School, University of Birmingham, Birmingham, UK., Kaiser M; Centre for Myeloma Research, Division of Molecular Pathology, Institute of Cancer Research, London, UK., Owen R; HMDS, St James's University Hospital, Leeds, UK., Auner HW; Department of Immunology and Inflammation, Imperial College London, London, UK.; Langmuir Centre for Myeloma Research, Imperial College London, London, UK., Cook G; Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK.; Leeds Cancer Centre, St James's University Hospital, Leeds, UK., Meads D; Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK., Olivier C; Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK., Barnard L; Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK., Lambkin R; Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK., Paterson A; Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK., Dawkins B; Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK., Chapman M; Department of Haematology, University of Cambridge, Cambridge, UK., Pratt G; Department of Haematology, Queen Elizabeth Hospital, Birmingham, UK., Popat R; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK., Jackson G; Northern Centre for Cancer Care, Freeman Hospital, Newcastle-Upon-Tyne, UK., Bygrave C; Department of Haematology, University Hospital of Wales, Cardiff, UK., Sive J; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK., de Tute R; HMDS, St James's University Hospital, Leeds, UK., Chantry A; Department of Haematology, Royal Hallamshire Hospital, Sheffield, UK., Parrish C; Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK., Cook M; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.; Bristol Myers Squibb, Boundry, Switzerland., Asher S; Department of Haematology, UCL Cancer Institute, London, UK., Yong K; Department of Haematology, UCL Cancer Institute, London, UK.

Publikováno v: BMJ open [BMJ Open] 2022 Nov 17; Vol. 12 (11), pp. e063037. Date of Electronic Publication: 2022 Nov 17.